FindTrial
Sign In

Lerapolturev

BIOLOGICAL5 trials

Sponsors

Istari Oncology, Inc., Darell Bigner

Conditions

Bladder CancerBrain TumorGlioblastomaMalignant GliomaMelanomaNon-muscle-invasive Bladder CancerRecurrent GlioblastomaRecurrent Supratentorial Glioblastoma

Phase 1

LUMINOS-103: A Basket Trial of Safety & Efficacy of Lerapolturev With or Without Checkpoint Inhibitors
TerminatedNCT04690699
Istari Oncology, Inc.Bladder Cancer, Non-muscle-invasive Bladder Cancer, Solid Tumor
Start: 2021-08-01End: 2024-06-12Updated: 2024-10-24

Phase 2

Lerapolturev in Recurrent Malignant Glioma
CompletedNCT02986178
Istari Oncology, Inc.Malignant Glioma
Start: 2017-06-01End: 2023-02-03Updated: 2025-07-11
LUMINOS-101: Lerapolturev (PVSRIPO) and Pembrolizumab in Patients With Recurrent Glioblastoma
CompletedNCT04479241
Istari Oncology, Inc.Brain Tumor, Glioblastoma, Recurrent Glioblastoma +1
Start: 2020-10-21End: 2024-06-21Updated: 2025-06-05
LUMINOS-102: Lerapolturev With or Without Immune Checkpoint Blockade in Advanced PD-1 Refractory Melanoma
CompletedNCT04577807
Istari Oncology, Inc.Melanoma
Start: 2020-11-17End: 2024-11-15Updated: 2025-09-19
Lerapolturev (PVSRIPO) in GBM
RecruitingNCT06177964
Darell BignerRecurrent Supratentorial Glioblastoma
Start: 2024-07-15End: 2029-02-01Target: 92Updated: 2026-07-20

Related Papers

Data from Lymphotropic Virotherapy Induces DC and High Endothelial Venule Inflammation, Promoting the Antitumor Efficacy of Intratumor Virus Administration
2026-02-03
Lymphotropic Virotherapy Induces DC and High Endothelial Venule Inflammation, Promoting the Antitumor Efficacy of Intratumor Virus Administration.
2025-11-21
TIP-25. Randomized phase 2 clinical trial of repeated intratumoral and cervical perilymphatic injections (CPLIs) of lerapolturev vs. lomustine in recurrent glioblastoma (rGBM): safety lead-in results
Neuro-Oncology2025-11-01
The safety and accuracy of intratumoral catheter placement to infuse viral immunotherapies in children with malignant brain tumors: a multi-institutional study
Journal of Neurosurgery Pediatrics2024-01-134 citations
Combined cytotoxic and immune-stimulatory gene therapy using Ad-TK and Ad-Flt3L: Translational developments from rodents to glioma patients.
2023-08-1214 citations
Multimodality analysis confers a prognostic benefit of a T-cell infiltrated tumor microenvironment and peripheral immune status in patients with melanoma
Journal for ImmunoTherapy of Cancer2022-09-0140 citations
Abstract 2073: Childhood vaccine-specific CD4+T cell recall coordinates antitumor type I and II immunity
Cancer Research2022-06-15
Abstract P045: LUMINOS-103: A basket trial evaluating the safety and efficacy of PVSRIPO and PVSRIPO in combination with anti-PD-1/L1 checkpoint inhibitors in patients with advanced solid tumors
Molecular Cancer Therapeutics2021-12-011 citations
739 Intratumor childhood vaccine-specific CD4+ T cell recall helps antitumor CD8 T cells
Regular and Young Investigator Award Abstracts2021-11-011 citations
517 LUMINOS-103: a basket trial evaluating the safety and efficacy of PVSRIPO and PVSRIPO in combination with anti-PD-1/L1 checkpoint inhibitors in patients with advanced solid tumors
Regular and Young Investigator Award Abstracts2021-11-01
Abstract CT242: LUMINOS-103: A basket trial evaluating the safety and efficacy of PVSRIPO in patients with advanced solid tumors
Cancer Research2021-07-012 citations
Abstract CT240: LUMINOS-101: Phase 2 study of PVSRIPO with pembrolizumab in recurrent glioblastoma
Cancer Research2021-07-01
LUMINOS-101: Phase 2 study of PVSRIPO with pembrolizumab in recurrent glioblastoma.
Journal of Clinical Oncology2021-05-2014 citations
Safety and efficacy of murine PVSRIPO plus anti-PD-1 immune checkpoint inhibitor (ICI) in a melanoma tumor model.
Journal of Clinical Oncology2021-05-201 citations